Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HuAb45
- Development stage
- Preclinical
- Lead developer
- Flemia Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
HuAb45 (humanized Ab45) is a humanized monoclonal antibody designed to neutralize the extracellular S100A8/A9 heterodimer complex (also known as calprotectin). Developed by researchers at Okayama University and its spinout Flemia Therapeutics, HuAb45 targets S100A8/A9, a key inflammatory alarmin implicated in severe inflammatory diseases, tissue fibrosis, and cancer metastasis. By blocking the interaction of S100A8/A9 with its receptors (such as TLR4, RAGE, and MCAM), HuAb45 suppresses downstream inflammatory signaling, neutrophil extracellular trap (NET) formation, and fibroblast activation. It is currently being investigated for the treatment of idiopathic pulmonary fibrosis (IPF), acute exacerbations of pulmonary fibrosis, contact hypersensitivity, and atopic dermatitis.
- Other names
- S100A8/A9-neutralizing antibody Ab45anti-S100A8/A9 neutralizing antibody Ab45humanized Ab45humanized Ab45 antibody
02
Targets
S100A8/S100A9 (S100A8/S100A9 heterodimer)
Beyond the preview
Go deeper on HuAb45.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HuAb45.